Do you want to read an article? Please log in or register.
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Multiple Myeloma (MM)
Indications
Related content
Multiple Myeloma (MM)
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
Lancet Haematol
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV, DREAMM-7 trial study group
doi: 10.1016/S2352-3026(25)00163-2
Multiple Myeloma (MM)
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
Lancet Haematol
Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J
doi: 10.1016/S2352-3026(25)00143-7
Multiple Myeloma (MM)
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
Eur J Cancer
Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B
doi: 10.1016/j.ejca.2024.115157
Multiple Myeloma (MM)
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Blood
Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong MME, Fokkema C, Smits F, Groen K, Verkleij CPM, Frerichs KA, Papazian N, van Duin M, van Beek G, Hoogenboezem R, Baardemans T, Dal Collo G, Stoetman ECG, Cosovic M, Twickler I, Rentenaar R, Eken M, Homan-Weert PM, Saraci E, D'Agostino M, van der Velden VHJ, Sanders MA, Gay F, Broijl A, Moreau P, Sonneveld P, Zweegman S, Mutis T, Cupedo T, van de Donk NWCJ
doi: 10.1182/blood.2024026455
Multiple Myeloma (MM)
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Lancet Haematol
Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M
doi: 10.1016/S2352-3026(25)00162-0
Further Publications
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
Ann Oncol
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G
doi: 10.1016/j.annonc.2025.03.019
Multiple Myeloma (MM)
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Lancet Oncol
Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T
doi: 10.1016/S1470-2045(25)00280-3
Multiple Myeloma (MM)
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
Blood Cancer J
Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Joshi P, Jou YM, Mouro J, Yu E, Abonour R
doi: 10.1038/s41408-024-01177-6
Multiple Myeloma (MM)
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
Blood Cancer J
Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C
doi: 10.1038/s41408-024-01185-6